GPRIN1

Across TCGA pan-cancer cohorts, GPRIN1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GPRIN1 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GPRIN1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GPRIN1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where GPRIN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.437	0.636	<.001	71	view →
CCRCC	OS	Quartile	III,IV	0.377	0.872	.009	10	view →
LSCC	OS	Tertile	III,IV	0.979	0.593	.012	6	view →
HNSC	OS	Quartile	IV	0.413	0.812	.017	4	view →
GBM	DFS	Quartile	All	0.871	0.670	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GPRIN1–PDAC (OS)

Open the PDAC breakdown →